DENGUE - SCI & TECH

News: Dengue vaccine: India moves closer to getting its first indigenous vaccine

 

What's in the news?

       Moving closer to being able to develop the country’s first vaccine against dengue, drug-makers Serum Institute of India and Panacea Biotec have applied to the Indian Council of Medical Research’s (ICMR) call for ‘Expression of Interest’ for collaborative Phase-III clinical trials for indigenous manufacturers.

 

Key takeaways:

       Phase-III clinical trial is being done for evaluation of efficacy, along with safety and immunogenicity of tetravalent dengue vaccine candidate developed by Indian manufacturers.

 

Dengue:

       Dengue is a mosquito-borne tropical disease caused by the dengue virus (Genus Flavivirus), transmitted by several species of female mosquito within the genus Aedes, principally Aedes aegypti.

       There are 4 distinct, but closely related, serotypes (separate groups within a species of microorganisms that all share a similar characteristic) of the virus that cause dengue (DEN-1, DEN-2, DEN-3 and DEN-4).

       Dengue is the world’s fastest-growing vector borne disease.

       Evidence shows over the past 50 years, there was a 30-50-fold increase in dengue cases in tropical and subtropical countries, like India.

 

Risk among populations:

       According to ICMR, dengue virus disease causes significant morbidity and mortality across the globe.

       In India, 2 to 2.5 lakh cases are reported annually.

       The global incidence of dengue has grown dramatically with about half of the world’s population now at risk.

       Although an estimated 100-400 million infections occur each year, over 80% are generally mild and asymptomatic.

 

Global threat:

       The World Health Organization (WHO) has identified dengue to be one among the top ten global health threats in 2019.

 

Vulnerability of Dengue:

       The virus is evolving too, and how the human body responds to it is becoming complex.

       The disease is becoming dangerous, not only due to human vulnerability but also climate change and urbanization.

       Climatic factors — including temperature, humidity and rainfall — impact the life cycle and transmission of vector-borne viruses (such as dengue and malaria), such that they are able to grow faster, survive for longer periods of time in the host population and spread to geographies without histories of reported infection.

 

Symptoms:

       Sudden high fever, severe headaches, pain behind the eyes, severe bone, joint, and muscle pain, etc.

 

Treatment:

       As of now, there is no specific treatment for dengue/severe dengue.